MedTrace Logo

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2023-10-04

No results posted yet for this study

Summary

This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

Conditions

  • Renal Anemia

Interventions

DRUG

AND017

Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2

DRUG

Placebo

Orally, 3 times per week

Sponsors & Collaborators

  • Kind Pharmaceuticals LLC

    lead INDUSTRY

Principal Investigators

  • Yusha Zhu, MD PhD · Kind Pharmaceuticals LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2023-07-05
Completion
2023-07-24
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035641 on ClinicalTrials.gov